The AP4M1 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population with disrupted AP4M1, creating a loss-of-function model for the ??1 subunit of the adaptor protein complex 4 (AP-4). Generated in the near-haploid human HAP1 fibroblast-like cell line, this knockout pool facilitates robust functional studies of AP-4-mediated cargo sorting from the trans-Golgi network (TGN) to endosomes, without requiring clonal isolation.
HAP1 cells are a human near-haploid fibroblast-like cell line derived from the KBM-7 chronic myeloid leukemia isolate, originally from a male patient. Their near-haploid karyotype simplifies gene knockout, as disruption of a single allele often results in complete loss of protein expression, making them an ideal host for genetic studies. The cells grow adherently and maintain key signaling and trafficking pathways, providing a physiologically relevant context for AP4M1 knockout experiments.
AP4M1 encodes the ??1 subunit of the heterotetrameric AP-4 complex, which also includes ??4 (AP4B1), ?? (AP4E1), and ??4 (AP4S1) subunits. This complex is recruited to the TGN by the small GTPase ARF1, where AP4M1 recognizes tyrosine-based (YXX??) and dileucine ([DE]XXXL[LI]) sorting signals on transmembrane cargo proteins such as ATG9A, CTNND2, and APP. AP4M1 directly binds these motifs, orchestrating packaging into vesicles destined for the endosomal system. Disruption of AP4M1 abrogates AP-4 assembly, leading to mislocalization of ATG9A, impaired autophagy flux, and defective endosomal sorting of AMPA receptors.
In the HAP1 cellular context, AP4M1 knockout provides a relevant model for investigating the molecular basis of AP-4 deficiency disorders, notably Hereditary Spastic Paraplegia 50 (SPG50) and AP-4 Deficiency Syndrome. These conditions are characterized by progressive spasticity and neurodevelopmental defects, partially attributed to disrupted autophagy and neuronal protein sorting. The knockout model allows detailed examination of ATG9A trafficking, LC3 lipidation, and CTNND2 localization, and supports functional rescue experiments to validate disease mechanisms and screen pharmacological correctors.
This polyclonal knockout population is suitable for a range of experimental applications, including immunofluorescence analysis of ATG9A subcellular distribution, co-immunoprecipitation of AP-4 complex components, Western blotting for AP4M1 loss, and autophagy flux assays using LC3 turnover. RT-qPCR can confirm transcript disruption, and the model is amenable to high-content screening for modulators of TGN-endosome trafficking. The AP4M1 Knockout HAP1 Polyclonal Cells thus offer a versatile tool for studying AP-4 biology, hereditary spastic paraplegia mechanisms, and drug discovery. For further details, contact Ascent Research.
